CRISPR Archives

Biotech Megan Molteni

PACT Pharma’s personalized cancer treatments, powered by CRISPR, clear early safety hurdles

Biotech Adam Feuerstein

FDA places clinical hold on Verve Therapeutics gene-editing treatment

Biotech Ryan Cross — The Boston Globe

Muscular dystrophy patient who was first in line for a custom CRISPR therapy dies

Special Report Matthew Herper

Here’s why we’re not prepared for the next wave of biotech innovation

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: Biden’s Covid declaration, twilight of the SPAC, & genome editing 2.0

Pharmalot Ed Silverman

Pharmalittle: CRISPR-based drug shows promise in preliminary study; FDA user fee program prompts fresh worries over conflicts

Biotech Megan Molteni

Intellia says CRISPR treatment safely corrects DNA of six patients with rare disease

The Readout LOUD Damian Garde and Adam Feuerstein

Listen: CRISPR for the heart, biotech’s recovery, & what it means to be a ‘hot girl’

First Opinion Eric B. Kmiec

Secrecy: A demon of gene therapy’s past bedevils its future

Biotech Jason Mast

Beyond a CRISPR treatment’s encouraging results, some scientists see a need for more data on risk

Biotech Adam Feuerstein

Updated study results show a CRISPR treatment for blood diseases continues to benefit patients

Biotech Adam Feuerstein

A Caribou CAR-T treatment, backed by Nobel-winning science, shows blood-cancer remissions in first data reveal

First Opinion Walter G. Johnson and Diana M. Bowman

It’s time for Congress to stop blocking mitochondrial replacement therapy

Biotech Megan Molteni

In the wake of big patent decision, it’s business as usual for CRISPR therapy developers

Exclusive Megan Molteni

New details emerge about a U.S. scientist’s obscured role in the ‘CRISPR babies’ scandal

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: Biden’s plans for Covid pills, the latest vaccine data, & fighting about CRISPR

First Opinion Lee D. Cooper

Rediscovering a language of healing that doesn’t require ‘cure’

Biotech Megan Molteni

3 burning questions spurred by the big CRISPR patent ruling

Biotech Megan Molteni

UC Berkeley loses CRISPR patent case, invalidating patent rights it granted gene-editing companies developing human therapies

Biotech Adam Feuerstein

Intellia Therapeutics shows improved, sustained effect from in vivo CRISPR treatment

Biotech Megan Molteni

With new trial data coming, Intellia CEO talks up the future of in vivo gene editing

Video Chat Matthew Herper

Virtual Event: CRISPR Quest

The Readout LOUD Damian Garde and Meg Tirrell

Jennifer Doudna and Marty Chavez on where CRISPR meets Wall Street

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: Robert Califf’s FDA return, the future of CRISPR, & another vaccine delay

In the Lab Megan Molteni

CRISPR

Most Read

A turnaround for Editas Medicine, a CRISPR laggard, hinges on updates on key treatments

A new suite of RNA-sensing tools could help scientists target cancerous cells, and much more

Biotech turns to new and strange viruses to overcome gene therapy’s limitations

After early wins, CRISPR gene editing is about to get a lot harder

New CRISPR startup, drawing big-name backers, seeks to fix diseases caused by large DNA errors

CRISPR debuted 10 years ago, in a paper hardly anyone noticed. Jennifer Doudna reflects on the DNA scissors’ first decade

Lab tests show risks of using CRISPR gene editing on embryos

You had questions for David Liu about CRISPR, prime editing, and advice to young scientists. He has answers

All Coverage

PACT Pharma’s personalized cancer treatments, powered by CRISPR, clear early safety hurdles

FDA places clinical hold on Verve Therapeutics gene-editing treatment

Muscular dystrophy patient who was first in line for a custom CRISPR therapy dies

Here’s why we’re not prepared for the next wave of biotech innovation

Listen: Biden’s Covid declaration, twilight of the SPAC, & genome editing 2.0

Pharmalittle: CRISPR-based drug shows promise in preliminary study; FDA user fee program prompts fresh worries over conflicts

Intellia says CRISPR treatment safely corrects DNA of six patients with rare disease

Listen: CRISPR for the heart, biotech’s recovery, & what it means to be a ‘hot girl’

Secrecy: A demon of gene therapy’s past bedevils its future

Beyond a CRISPR treatment’s encouraging results, some scientists see a need for more data on risk

Updated study results show a CRISPR treatment for blood diseases continues to benefit patients

A Caribou CAR-T treatment, backed by Nobel-winning science, shows blood-cancer remissions in first data reveal

It’s time for Congress to stop blocking mitochondrial replacement therapy

In the wake of big patent decision, it’s business as usual for CRISPR therapy developers

New details emerge about a U.S. scientist’s obscured role in the ‘CRISPR babies’ scandal

Listen: Biden’s plans for Covid pills, the latest vaccine data, & fighting about CRISPR

Rediscovering a language of healing that doesn’t require ‘cure’

3 burning questions spurred by the big CRISPR patent ruling

UC Berkeley loses CRISPR patent case, invalidating patent rights it granted gene-editing companies developing human therapies

Intellia Therapeutics shows improved, sustained effect from in vivo CRISPR treatment

With new trial data coming, Intellia CEO talks up the future of in vivo gene editing

Virtual Event: CRISPR Quest

Jennifer Doudna and Marty Chavez on where CRISPR meets Wall Street

Listen: Robert Califf’s FDA return, the future of CRISPR, & another vaccine delay

Drugs based on next-generation gene editing are moving toward the clinic faster than CRISPR 1.0

You've been selected! STAT+ for less than $2/day

Subscribe to STAT+ for less than $2 per day